MCID: DFF016
MIFTS: 57

Diffuse Astrocytoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Diffuse Astrocytoma

MalaCards integrated aliases for Diffuse Astrocytoma:

Name: Diffuse Astrocytoma 11 19 58 14
Diffuse Astrocytoma, Low Grade 11
Low-Grade Diffuse Astrocytoma 19
Who Grade Ii Astrocytoma 11
Gemistocytic Astrocytoma 19
Protoplasmic Astrocytoma 19
Fibrillary Astrocytoma 19

Characteristics:


Prevelance:

1-9/1000000 (United States) 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:4857
NCIt 49 C7173
ICD10 via Orphanet 32 C71.9
UMLS via Orphanet 72 C0280785
Orphanet 58 ORPHA251595

Summaries for Diffuse Astrocytoma

GARD: 19 A rare low-grade astrocytoma characterized by a high degree of cellular differentiation, slow growth, and diffuse infiltration of adjacent brain structures, and corresponding to WHO grade II. The tumor typically affects young adults and has an intrinsic tendency for progression to high-grade glioma. Histological variants are fibrillary, gemistocytic, and protoplasmic astrocytoma. Patients most commonly present with seizures, but also with other neurological or neuropsychological abnormalities, depending on the location.

MalaCards based summary: Diffuse Astrocytoma, also known as diffuse astrocytoma, low grade, is related to protoplasmic astrocytoma and fibrillary astrocytoma. An important gene associated with Diffuse Astrocytoma is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1), and among its related pathways/superpathways are Signal Transduction and Prolactin Signaling. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and spinal cord, and related phenotypes are Decreased viability in pancreas lineage and homeostasis/metabolism

Orphanet: 58 A rare low-grade astrocytoma characterized by a high degree of cellular differentiation, slow growth, and diffuse infiltration of adjacent brain structures, and corresponding to WHO grade II. The tumor typically affects young adults and has an intrinsic tendency for progression to high-grade glioma. Histological variants are fibrillary, gemistocytic, and protoplasmic astrocytoma. Patients most commonly present with seizures, but also with other neurological or neuropsychological abnormalities, depending on the location.

Disease Ontology: 11 A low grade glioma that is characterized by diffuse infiltration of neighboring central nervous system structures.

Related Diseases for Diffuse Astrocytoma

Diseases related to Diffuse Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 440)
# Related Disease Score Top Affiliating Genes
1 protoplasmic astrocytoma 33.0 MGMT IDH2
2 fibrillary astrocytoma 31.6 TP53 NF1 KIAA1549 IDH2 IDH1 H3-3B
3 glioma susceptibility 1 31.5 TP53 IDH2 IDH1 H3-3A
4 subependymal giant cell astrocytoma 30.5 NF1 KIAA1549 GFAP
5 gliofibroma 30.4 KIAA1549 GFAP
6 oligoastrocytoma 30.2 MGMT IDH2 GFAP
7 gemistocytic astrocytoma 30.1 TP53 MGMT IDH2 IDH1 GFAP ATRX
8 cerebellar astrocytoma 30.1 SERPINA3 NF1 KIAA1549 IDH1 H3-3A
9 neurofibromatosis 30.0 TP53 PDGFRA NF1 EGFR CDKN2A
10 ganglioglioma 30.0 TP53 NF1 H3-3A GFAP
11 glioma 29.9 TP53 NF1 MGMT IDH2 IDH1 EGFR
12 bap1 tumor predisposition syndrome 29.9 TP53 TERT NF1 EGFR CDKN2A
13 neurofibromatosis, type i 29.8 TP53 PDGFRA NF1 KIAA1549 IDH1 EGFR
14 melanoma, cutaneous malignant 1 29.8 TP53 TERT NF1 MGMT EGFR CDKN2A
15 malignant peripheral nerve sheath tumor 29.7 TP53 TERT PDGFRA NF1 EGFR CDKN2A
16 diffuse midline glioma, h3 k27m-mutant 29.6 TP53 PDGFRA OLIG2 MGMT IDH1 H3-3B
17 malignant astrocytoma 29.6 TP53 SERPINA3 MGMT KDM4C IDH1 H2AC18
18 glioblastoma 29.4 TP53 TERT PDGFRA OLIG2 NF1 MGMT
19 high grade glioma 29.2 TP53 TERT PDGFRA MGMT KDM4C H2AC18
20 oligodendroglioma 29.2 TP53 TERT PDGFRA OLIG2 NF1 MGMT
21 pleomorphic xanthoastrocytoma 29.1 TP53 TERT SERPINA3 NF1 MYBL1 MGMT
22 brain cancer 28.9 TP53 TERT PDGFRA OLIG2 NF1 MGMT
23 gliosarcoma 28.7 TP53 TERT SERPINA3 PDGFRA OLIG2 NF1
24 meningioma, familial 28.7 TP53 TERT SERPINA3 OLIG2 NF1 MGMT
25 giant cell glioblastoma 28.7 TP53 TERT SERPINA3 PDGFRA OLIG2 NF1
26 pilocytic astrocytoma 28.6 TP53 TERT SERPINA3 PDGFRA OLIG2 NF1
27 anaplastic astrocytoma 28.5 TP53 TERT SERPINA3 PDGFRA OLIG2 NF1
28 low grade glioma 28.1 TP53 TERT SERPINA3 PDGFRA OLIG2 NF1
29 glial tumor 11.1
30 enchondroma 10.5 IDH2 IDH1
31 high-grade astrocytoma 10.4 TP53 ATRX
32 thalamic neoplasm 10.4 MYBL1 KIAA1549
33 simple partial epilepsy 10.4 KIAA1549 IDH1
34 intracranial chondrosarcoma 10.4 IDH2 IDH1
35 anaplastic oligodendroglioma, idh-mutant and 1p/19q-codeleted 10.4 IDH2 IDH1
36 adult spinal cord glioblastoma multiforme 10.4 TERT MGMT
37 2-hydroxyglutaric aciduria 10.4 KDM4C IDH2 IDH1
38 optic nerve astrocytoma 10.4 NF1 IDH1
39 tonsillar pillar cancer 10.4 EGFR CDKN2A
40 periosteal chondrosarcoma 10.4 IDH2 IDH1
41 d-2-hydroxyglutaric aciduria 2 10.4 IDH2 IDH1 H2AC18
42 juxtacortical chondroma 10.4 IDH2 IDH1
43 angioimmunoblastic t-cell lymphoma 10.4 KDM4C IDH2 IDH1
44 l-2-hydroxyglutaric aciduria 10.4 KDM4C IDH2 IDH1
45 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 10.4 TP53 CDKN2A
46 endometrial squamous cell carcinoma 10.4 TP53 CDKN2A
47 sinonasal undifferentiated carcinoma 10.4 IDH2 IDH1 CDKN2A
48 bone giant cell sarcoma 10.3 TP53 H3-3B H3-3A
49 prolactin producing pituitary tumor 10.3 TP53 MGMT
50 keratosis pilaris atrophicans faciei 10.3 NF1 EGFR

Graphical network of the top 20 diseases related to Diffuse Astrocytoma:



Diseases related to Diffuse Astrocytoma

Symptoms & Phenotypes for Diffuse Astrocytoma

GenomeRNAi Phenotypes related to Diffuse Astrocytoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in pancreas lineage GR00235-A 8.8 IDH1 MYBL1 TP53

MGI Mouse Phenotypes related to Diffuse Astrocytoma:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.37 CDKN2A EGFR GFAP H3-3A H3-3B IDH1
2 growth/size/body region MP:0005378 10.35 ATRX CDKN2A EGFR FUBP1 GFAP H3-3A
3 nervous system MP:0003631 10.29 ATRX CDKN2A EGFR FUBP1 GFAP IDH1
4 neoplasm MP:0002006 10.25 CDKN2A EGFR IDH2 KDM4C MGMT NF1
5 cellular MP:0005384 10.25 ATRX CDKN2A EGFR GFAP H3-3A H3-3B
6 normal MP:0002873 10.19 EGFR GFAP H3-3A H3-3B MYBL1 NF1
7 behavior/neurological MP:0005386 10.18 ATRX CDKN2A FUBP1 GFAP H3-3A H3-3B
8 immune system MP:0005387 10.17 CDKN2A EGFR FUBP1 GFAP IDH1 IDH2
9 endocrine/exocrine gland MP:0005379 10.16 CDKN2A EGFR FUBP1 KDM4C MGMT MYBL1
10 embryo MP:0005380 10.09 ATRX CDKN2A EGFR FUBP1 H3-3A H3-3B
11 no phenotypic analysis MP:0003012 10.07 CDKN2A EGFR KDM4C MGMT OLIG2 PDGFRA
12 respiratory system MP:0005388 9.96 CDKN2A EGFR FUBP1 IDH1 MGMT NF1
13 hematopoietic system MP:0005397 9.93 CDKN2A EGFR FUBP1 IDH1 IDH2 KDM4C
14 mortality/aging MP:0010768 9.83 ATRX CDKN2A EGFR FUBP1 GFAP H3-3A
15 integument MP:0010771 9.28 CDKN2A EGFR FUBP1 KDM4C MYBL1 NF1

Drugs & Therapeutics for Diffuse Astrocytoma

Drugs for Diffuse Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760
3 Protein Kinase Inhibitors Phase 4
4
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
5
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
6
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
7
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
8
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
9
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
10
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
11
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
12
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
13
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3 135329020
14
Cetuximab Approved Phase 1, Phase 2 205923-56-4
15
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
16 Immunosuppressive Agents Phase 2
17 Vaccines Phase 2
18 Anti-Bacterial Agents Phase 1, Phase 2
19 Anti-Infective Agents Phase 1, Phase 2
20 Antifungal Agents Phase 1, Phase 2
21 Antibiotics, Antitubercular Phase 1, Phase 2
22 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
23 Alkylating Agents Phase 2
24 Antineoplastic Agents, Alkylating Phase 2
25 Antimitotic Agents Phase 2
26 Tubulin Modulators Phase 2
27 Immunoglobulins, Intravenous Phase 2
28 Immunoglobulins Phase 2
29 Antibodies, Monoclonal Phase 2
30 Antibodies Phase 2
31 Immunologic Factors Phase 2
32 Immunoglobulin G Phase 2
33 Angiogenesis Inhibitors Phase 1, Phase 2
34 Antineoplastic Agents, Immunological Phase 1, Phase 2
35
Erlotinib Approved, Investigational Phase 1 183319-69-9, 183321-74-6 176870
36
Isotretinoin Approved, Investigational, Nutraceutical Phase 1 302-79-4, 4759-48-2 5538 444795 5282379
37
Etanidazole Investigational Phase 1 22668-01-5 3276
38 Liver Extracts Phase 1
39 R04929097 Phase 1
40 Fluorides Phase 1
41 Dermatologic Agents Phase 1
42
Dopamine Approved 62-31-7, 51-61-6 681
43
Edetate calcium disodium anhydrous Approved, Vet_approved 62-33-9, 60-00-4 6049
44
Iron Approved 7439-89-6 29936
45
Pentetic acid Approved 67-43-6
46
Imidazole Experimental, Investigational 288-32-4 795
47 Dihydroxyphenylalanine
48 Neurotransmitter Agents
49 Dopamine Agents
50 Iron Chelating Agents

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
3 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2 Everolimus
4 A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Completed NCT00499473 Phase 2 sunitinib malate
5 A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Low-grade Glioma Completed NCT01635283 Phase 2
6 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
7 Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
8 Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas Completed NCT01051557 Phase 1, Phase 2 Perifosine;Temsirolimus
9 A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG) Completed NCT01514201 Phase 1, Phase 2 Temozolomide;Veliparib
10 Phase II Trial of Treatment Intensification for IDH Wildtype, Non-Histological Glioblastoma, Gliomas (IDH Wildtype Lower Grade Glioma Treatment Intensification) Recruiting NCT04623931 Phase 2 Temozolomide
11 A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas Recruiting NCT03180502 Phase 2 Temozolomide
12 Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG) Active, not recruiting NCT02684058 Phase 2 dabrafenib;trametinib;Carboplatin with vincristine
13 A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Suspended NCT04729959 Phase 2
14 Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux (Cetuximab) And Avastin (Bevacizumab)For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age Terminated NCT01884740 Phase 1, Phase 2 SIACI of Erbitux and Bevacizumab
15 Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
16 Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
17 Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas Completed NCT02186509 Phase 1 Alisertib
18 A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Recruiting NCT04541082 Phase 1 ONC206
19 A Phase 1, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Central Nervous System (CNS) Penetration of CC-90010 in Preoperative Subjects With Progressive or Recurrent Who Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and Recurrent Glioblastoma Scheduled for Resection Active, not recruiting NCT04047303 Phase 1 CC-90010
20 A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma Active, not recruiting NCT03528642 Phase 1 Telaglenastat Hydrochloride;Temozolomide
21 Microenvironment: Imaging/Implications in Brain Tumors; A Preliminary Investigation of the Biodistribution of [F-18]-EF5 in Patients With Brain Tumors Terminated NCT00110032 Phase 1 EF5
22 A Phase I Single Arm Open Label Study of Erlotinib and 13-cis-Retinoic Acid (CRA) in Patients With Recurrent Malignant Gliomas Terminated NCT01103375 Phase 1 erlotinib hydrochloride;isotretinoin
23 Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in Patients With Supratentorial Low-Risk Grade II Glioma Completed NCT01417507
24 PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas Recruiting NCT05190172
25 A Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma Recruiting NCT04065776
26 A Pilot Study of Utility of 18F-FDOPA-PET for Neurosurgical Planning and Radiotherapy Target Delineation in Glioma Patients: Biopsy Validation of 18F-FDOPA-PET Uptake and Biodistribution in Brain Tumors Active, not recruiting NCT01165632 Early Phase 1 fluorine F 18 fluorodopa
27 Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma: a Longitudinal Study Based on Long-term Follow-up Not yet recruiting NCT05532969
28 18F-FDOPA PET/CT or PET/MRI in Patients With Gliomas Terminated NCT02175745 18F-fluoro-dihydroxyphenylalanine
29 Dynamic Contrast Enhanced Steady State T1-Weighted Perfusion MRI (DCE MRI): Characterization of Intracranial Lesions Terminated NCT02967380 Gadobenate Dimeglumine;Gadobutrol
30 Assessment of Hypoxia in Malignant Gliomas Using EF5 Terminated NCT00430079 etanidazole
31 Yoga and Brain Cancer: A Feasibility Study Terminated NCT01234805
32 Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Withdrawn NCT02194452

Search NIH Clinical Center for Diffuse Astrocytoma

Genetic Tests for Diffuse Astrocytoma

Anatomical Context for Diffuse Astrocytoma

Organs/tissues related to Diffuse Astrocytoma:

MalaCards : Brain, Eye, Spinal Cord, Liver, Temporal Lobe, Medulla Oblongata, Pineal

Publications for Diffuse Astrocytoma

Articles related to Diffuse Astrocytoma:

(show top 50) (show all 708)
# Title Authors PMID Year
1
The genomic landscape of dysembryoplastic neuroepithelial tumours and a comprehensive analysis of recurrent cases. 62
35836307 2022
2
Pediatric-type diffuse low-grade glioma with MYB/MYBL1 alteration: report of 2 cases. 62
36074655 2022
3
Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma. 62
36172668 2022
4
T2-Fluid-Attenuated Inversion Recovery (FLAIR) Mismatch as a Novel Specific MRI Marker for Adult Low-Grade Glioma (LGG): A Case Report. 62
36299937 2022
5
Atypical NMDA receptor expression in a diffuse astrocytoma, MYB- or MYBL1-altered as a trigger for autoimmune encephalitis. 62
35727368 2022
6
MR Imaging Characteristics and ADC Histogram Metrics for Differentiating Molecular Subgroups of Pediatric Low-Grade Gliomas. 62
36007944 2022
7
Germ cell tumors with neuroglial differentiation do not show molecular features akin to their central nervous system counterpart: experience from extra-gynecological sites. 62
35678876 2022
8
Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): An immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors. 62
35567887 2022
9
The 2021 WHO Classification of Tumors of the Central Nervous System: An update on pediatric low-grade gliomas and glioneuronal tumors. 62
35218102 2022
10
The Mean ApoC1 Serum Level in Postoperative Samples from Neurosurgical Patients Is Lower than in Preoperative Samples and during Chemotherapy. 62
36101402 2022
11
5-Aminolevulinic Acid-A Biomarker for Worse Prognosis in IDH-Wildtype II Tumors? Evolution of a Fluorescence-Positive Diffuse Astrocytoma: A Case Report. 62
36032798 2022
12
True anaplastic oligoastrocytoma with dual genotype: illustrative case. 62
36046704 2022
13
Polish and New Zealand Propolis as Sources of Antioxidant Compounds Inhibit Glioblastoma (T98G, LN-18) Cell Lines and Astrocytoma Cells Derived from Patient. 62
35883797 2022
14
A case of ganglioglioma grade 3 with H3 K27M mutation arising in the medial temporal lobe in an elderly patient. 62
35187715 2022
15
Pediatric-type diffuse low grade gliomas: Histomolecular profile and practical approach to their integrated diagnosis according to the WHO CNS5 classification. 62
35562133 2022
16
The persistence of seizures after tumor resection negatively affects survival in low-grade glioma patients: a clinical retrospective study. 62
34693462 2022
17
Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma. 62
35505351 2022
18
Epidemiological characteristics of central nervous system tumors in children: a 5-year review of 3180 cases from Beijing Tiantan Hospital. 62
35550659 2022
19
FISH analyses for 1p and 19q status on gliomas: Reporting an 8 years' experience from a tertiary care center in the Middle East. 62
35063798 2022
20
Combined Treatment With Radiotherapy and Immunotherapy for Isocitrate Dehydrogenase Mutant Brainstem Glioma in Adult: A Case Report. 62
35545834 2022
21
Young adult males have worse survival than females that is largely independent of treatment received for many types of central nervous system tumors: A National Cancer Database analysis. 62
35132626 2022
22
Frequent FGFR1 hotspot alterations in driver-unknown low-grade glioma and mixed neuronal-glial tumors. 62
35018490 2022
23
Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. 62
34718782 2022
24
β-Catenin marks proliferating endothelial cells in glioblastoma. 62
35189545 2022
25
Awake Surgery With Visual Pathway Mapping in Low Grade Glioma Surgery. 62
35308657 2022
26
An Updated Comparison Between World Health Organization Grade II Gemistocytic and Diffuse Astrocytoma Survival and Treatment Patterns. 62
34844008 2022
27
Rare simultaneous occurrence of a ganglioglioma and diffuse astrocytoma with distinct molecular features in a teenager with neurofibromatosis type 1. 62
35228248 2022
28
Diffuse astrocytoma with mosaic IDH1-R132H-mutant immuno-phenotype and low subclonal allele frequency. 62
35261853 2022
29
Reclassification of Glioblastoma Multiforme According to the 2021 World Health Organization Classification of Central Nervous System Tumors: A Single Institution Report and Practical Significance. 62
35291535 2022
30
[Algorithm for the integrated diagnosis of gliomas 2021. Our experience]. 62
35639057 2022
31
Cytopathological and histopathological features of cerebral granular cell astrocytoma: A case report. 62
34608699 2022
32
Alpha2beta1 Integrin Polymorphism in Diffuse Astrocytoma Patients. 62
35936750 2022
33
Early atypical malignant transformation of diffuse low-grade astrocytoma: The importance of genotyping. 62
34998489 2022
34
An MRI-based joint model of radiomics and spatial distribution differentiates autoimmune encephalitis from low-grade diffuse astrocytoma. 62
36408523 2022
35
Surgical techniques and function outcome for cingulate gyrus glioma, how we do it. 62
36226056 2022
36
Spatial concordance of DNA methylation classification in diffuse glioma. 62
34049406 2021
37
Radiologic-pathologic association of tumor-like lesions with inflammation in cerebral white matter: Comparison of two cases with distinct clinical outcomes. 62
34791710 2021
38
Molecular Alterations in Pediatric Low-Grade Gliomas That Led to Death. 62
34580728 2021
39
Fractal analysis of 11C-methionine PET in patients with newly diagnosed glioma. 62
34743250 2021
40
Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system. 62
34374800 2021
41
Differential expression of stem cell markers in proliferating cells in glioma. 62
34170383 2021
42
Pediatric thalamic incidentalomas: an international retrospective multicenter study. 62
34715651 2021
43
Atomic Force Microscope Nanoindentation Analysis of Diffuse Astrocytic Tumor Elasticity: Relation with Tumor Histopathology. 62
34572766 2021
44
Molecular Landscape for Malignant Transformation in Diffuse Astrocytoma. 62
34430964 2021
45
Eslicarbazepine in patients with brain tumor-related epilepsy: a single-center experience. 62
32316814 2021
46
Tumor treating fields combined with a poly (adenosine diphosphate-ribose) polymerase inhibitor during radiotherapy for rapidly progressing IDH-wildtype diffuse astrocytoma: a case report. 62
34407687 2021
47
Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas. 62
34141429 2021
48
Diffuse Gliomas of the Brainstem and Cerebellum in Adults Show Molecular Heterogeneity. 62
33606385 2021
49
Illustration of the Added Value of 18F-DOPA PET to Multimodal MRI to Distinguish Low- and High-Grade Gliomas. 62
33577196 2021
50
IDH-mutant gliomas with additional class-defining molecular events. 62
33772213 2021

Variations for Diffuse Astrocytoma

Cosmic variations for Diffuse Astrocytoma:

8 (show top 50) (show all 20596)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM85192834 ZW10 central nervous system,brain,glioma,astrocytoma Grade IV c.2140C>T p.P714S 11:113736699-113736699 6
2 COSM86922763 ZSWIM4 central nervous system,brain,glioma,astrocytoma Grade IV c.266C>T p.P89L 19:13799832-13799832 6
3 COSM88263742 ZRSR2 central nervous system,brain,glioma,astrocytoma Grade IV c.340C>T p.Q114* 23:15804138-15804138 6
4 COSM88261602 ZRSR2 central nervous system,brain,glioma,astrocytoma Grade IV c.961C>T p.P321S 23:15822754-15822754 6
5 COSM88263021 ZRSR2 central nervous system,brain,glioma,astrocytoma Grade IV c.260G>A p.R87K 23:15803744-15803744 6
6 COSM88261596 ZRSR2 central nervous system,brain,glioma,astrocytoma Grade IV c.271G>A p.E91K 23:15803755-15803755 6
7 COSM88262556 ZRSR2 central nervous system,brain,glioma,NS c.220G>A p.E74K 23:15803704-15803704 6
8 COSM87830624 ZPLD1 central nervous system,brain,glioma,astrocytoma Grade IV c.393A>T p.G131= 3:102456210-102456210 6
9 COSM119316158 ZPLD1 central nervous system,brain,glioma,astrocytoma Grade IV c.345A>T p.G115= 3:102456210-102456210 6
10 COSM116178212 ZPLD1 central nervous system,brain,glioma,astrocytoma Grade IV c.345A>T p.G115= 3:102456210-102456210 6
11 COSM106156998 ZNF697 central nervous system,brain,glioma,astrocytoma Grade IV c.1550G>A p.G517D 1:119622793-119622793 6
12 COSM93171584 ZNF687 central nervous system,brain,glioma,astrocytoma Grade IV c.3651C>T p.T1217= 1:151291146-151291146 6
13 COSM93173649 ZNF687 central nervous system,brain,glioma,astrocytoma Grade IV c.2044T>A p.C682S 1:151288335-151288335 6
14 COSM93173639 ZNF687 central nervous system,brain,glioma,astrocytoma Grade IV c.2043G>C p.Q681H 1:151288334-151288334 6
15 COSM92762364 ZNF507 central nervous system,brain,glioma,astrocytoma Grade IV c.1517G>C p.R506T 19:32354347-32354347 6
16 COSM91851905 ZNF507 central nervous system,brain,glioma,astrocytoma Grade IV c.1517G>C p.R506T 19:32354347-32354347 6
17 COSM130988554 ZNF507 central nervous system,brain,glioma,astrocytoma Grade IV c.1517G>C p.R506T 19:32354347-32354347 6
18 COSM141250987 ZNF473 central nervous system,brain,glioma,astrocytoma Grade IV c.42C>T p.D14= 19:50039193-50039193 6
19 COSM84172269 ZNF473 central nervous system,brain,glioma,astrocytoma Grade IV c.42C>T p.D14= 19:50039193-50039193 6
20 COSM141790125 ZNF473 central nervous system,brain,glioma,astrocytoma Grade IV c.42C>T p.D14= 19:50039193-50039193 6
21 COSM99924035 ZNF473 central nervous system,brain,glioma,astrocytoma Grade IV c.42C>T p.D14= 19:50039193-50039193 6
22 COSM111538647 ZNF473 central nervous system,brain,glioma,astrocytoma Grade IV c.6C>T p.D2= 19:50039193-50039193 6
23 COSM84507966 ZNF276 central nervous system,brain,glioma,astrocytoma Grade IV c.*664G>A p.? 16:89738910-89738910 6
24 COSM102909520 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2116G>A p.D706N 20:47246116-47246116 6
25 COSM116582422 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2176G>A p.D726N 20:47246116-47246116 6
26 COSM92864918 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2102T>G p.V701G 20:47246130-47246130 6
27 COSM111370233 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2116G>A p.D706N 20:47246116-47246116 6
28 COSM91410147 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2116G>A p.D706N 20:47246116-47246116 6
29 COSM97055096 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.1913T>G p.V638G 20:47246130-47246130 6
30 COSM112970642 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2176G>A p.D726N 20:47246116-47246116 6
31 COSM92871777 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2116G>A p.D706N 20:47246116-47246116 6
32 COSM85475347 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2102T>G p.V701G 20:47246130-47246130 6
33 COSM143801239 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2041G>A p.D681N 20:47246116-47246116 6
34 COSM114834078 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2087T>G p.V696G 20:47246130-47246130 6
35 COSM114839982 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2101G>A p.D701N 20:47246116-47246116 6
36 COSM91535436 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2176G>A p.D726N 20:47246116-47246116 6
37 COSM91528627 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2162T>G p.V721G 20:47246130-47246130 6
38 COSM133275210 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.1960G>A p.D654N 20:47246116-47246116 6
39 COSM143618110 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2116G>A p.D706N 20:47246116-47246116 6
40 COSM111362863 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2102T>G p.V701G 20:47246130-47246130 6
41 COSM91401933 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2102T>G p.V701G 20:47246130-47246130 6
42 COSM130874736 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2197G>A p.D733N 20:47246116-47246116 6
43 COSM116576154 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2162T>G p.V721G 20:47246130-47246130 6
44 COSM143862983 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2101G>A p.D701N 20:47246116-47246116 6
45 COSM143796197 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2027T>G p.V676G 20:47246130-47246130 6
46 COSM102902986 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2102T>G p.V701G 20:47246130-47246130 6
47 COSM133265728 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.1946T>G p.V649G 20:47246130-47246130 6
48 COSM85483642 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2116G>A p.D706N 20:47246116-47246116 6
49 COSM112964306 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2162T>G p.V721G 20:47246130-47246130 6
50 COSM143856741 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade IV c.2087T>G p.V696G 20:47246130-47246130 6

Expression for Diffuse Astrocytoma

Search GEO for disease gene expression data for Diffuse Astrocytoma.

Pathways for Diffuse Astrocytoma

Pathways related to Diffuse Astrocytoma according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1 13.52 EGFR GFAP H2AC18 H3-3A H3-3B KDM4C
2
Show member pathways
13.25 TP53 PDGFRA NF1 MGMT H3-3B H3-3A
3
Show member pathways
13.13 TP53 PDGFRA NF1 KIAA1549 IDH1 H3-3B
4
Show member pathways
12.59 TP53 H3-3B H3-3A H2AC18 EGFR
5
Show member pathways
12.53 TP53 H3-3B H3-3A H2AC18 CDKN2A
6 12.49 TP53 TERT PDGFRA EGFR CDKN2A
7
Show member pathways
11.96 TERT H3-3B H3-3A H2AC18 ATRX
8 11.61 PDGFRA OLIG2 GFAP
9 11.48 TP53 MYBL1 ATRX
10 11.21 TP53 EGFR CDKN2A
11 11.11 TP53 H3-3B H3-3A
12
Show member pathways
11.03 H3-3B H3-3A CDKN2A
13 10.97 TP53 H3-3B H3-3A EGFR
14 10.79 TP53 TERT EGFR CDKN2A

GO Terms for Diffuse Astrocytoma

Biological processes related to Diffuse Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of miRNA transcription GO:1902895 9.77 TP53 TERT EGFR
2 isocitrate metabolic process GO:0006102 9.56 IDH2 IDH1
3 Schwann cell proliferation GO:0014010 9.46 NF1 GFAP
4 positive regulation of miRNA maturation GO:1903800 9.32 TP53 EGFR
5 glyoxylate cycle GO:0006097 9.26 IDH2 IDH1
6 replicative senescence GO:0090399 9.1 TP53 TERT CDKN2A

Molecular functions related to Diffuse Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.55 TP53 TERT SERPINA3 OLIG2 MYBL1 MGMT
2 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.26 IDH2 IDH1

Sources for Diffuse Astrocytoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....